GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
November 21, 2024 08:45 ET
|
GRI Bio, Inc.
Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit Data demonstrate that NKT cells are activated in airways in IPF patients and...
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
November 14, 2024 16:20 ET
|
GRI Bio, Inc.
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline...
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
October 24, 2024 08:30 ET
|
GRI Bio, Inc.
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of...
GRI Bio Announces Exercise of Warrants
October 21, 2024 17:35 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
October 16, 2024 08:45 ET
|
GRI Bio, Inc.
Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis ...
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
October 07, 2024 08:30 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
September 30, 2024 08:30 ET
|
GRI Bio, Inc.
Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE...
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
September 26, 2024 08:00 ET
|
GRI Bio, Inc.
MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment...
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
September 25, 2024 08:45 ET
|
GRI Bio, Inc.
Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
GRI Bio Participates in Virtual Investor KOL Connect Segment
September 18, 2024 09:00 ET
|
GRI Bio, Inc.
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey,...